Clinical trial
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage…
NCT00114192 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00114192 |
|---|---|
| Title | Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, thalidomide |
| Enrollment | 37 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2007 |
| First posted | Jun 14, 2005 |
| Last update posted | Feb 1, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: